MX2020003666A - Compuestos y composiciones para el tratamiento de trastornos hematologicos. - Google Patents

Compuestos y composiciones para el tratamiento de trastornos hematologicos.

Info

Publication number
MX2020003666A
MX2020003666A MX2020003666A MX2020003666A MX2020003666A MX 2020003666 A MX2020003666 A MX 2020003666A MX 2020003666 A MX2020003666 A MX 2020003666A MX 2020003666 A MX2020003666 A MX 2020003666A MX 2020003666 A MX2020003666 A MX 2020003666A
Authority
MX
Mexico
Prior art keywords
compounds
hematological disorders
compositions
treating hematological
treating
Prior art date
Application number
MX2020003666A
Other languages
English (en)
Inventor
Robert Booher
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of MX2020003666A publication Critical patent/MX2020003666A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona métodos para tratar trastornos hematológicos y tumores malignos solidos usando compuestos de indazol sustituidos y sales farmacéuticamente aceptables de estos. Los compuestos inhiben las cinasas IRAK4 y BCL-2.
MX2020003666A 2017-10-31 2018-10-30 Compuestos y composiciones para el tratamiento de trastornos hematologicos. MX2020003666A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762579502P 2017-10-31 2017-10-31
PCT/US2018/058194 WO2019089580A1 (en) 2017-10-31 2018-10-30 Compounds and compositions for treating hematological disorders

Publications (1)

Publication Number Publication Date
MX2020003666A true MX2020003666A (es) 2020-08-03

Family

ID=66328095

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020003666A MX2020003666A (es) 2017-10-31 2018-10-30 Compuestos y composiciones para el tratamiento de trastornos hematologicos.
MX2023010882A MX2023010882A (es) 2017-10-31 2020-07-13 Compuestos y composiciones para el tratamiento de trastornos hematológicos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023010882A MX2023010882A (es) 2017-10-31 2020-07-13 Compuestos y composiciones para el tratamiento de trastornos hematológicos.

Country Status (26)

Country Link
US (3) US10758518B2 (es)
EP (2) EP3704108B1 (es)
JP (3) JP7241747B2 (es)
KR (2) KR20240130818A (es)
CN (2) CN111225911B (es)
AU (3) AU2018359248B2 (es)
BR (1) BR112020008214A2 (es)
CA (1) CA3079628A1 (es)
DK (1) DK3704108T3 (es)
EA (1) EA202090497A1 (es)
ES (1) ES2979273T3 (es)
FI (1) FI3704108T3 (es)
HR (1) HRP20240700T1 (es)
HU (1) HUE067356T2 (es)
IL (3) IL308364B2 (es)
LT (1) LT3704108T (es)
MX (2) MX2020003666A (es)
MY (1) MY203827A (es)
PH (1) PH12020550457A1 (es)
PL (1) PL3704108T3 (es)
PT (1) PT3704108T (es)
RS (1) RS65572B1 (es)
SG (1) SG11202002386WA (es)
SI (1) SI3704108T1 (es)
SM (1) SMT202400216T1 (es)
WO (1) WO2019089580A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202400142T1 (it) 2014-01-13 2024-05-14 Aurigene Oncology Ltd Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro
CN120267671A (zh) 2017-03-31 2025-07-08 奥锐金肿瘤有限公司 用于治疗血液病的化合物和组合物
MX2020003666A (es) * 2017-10-31 2020-08-03 Curis Inc Compuestos y composiciones para el tratamiento de trastornos hematologicos.
CN114391013B (zh) * 2019-09-24 2024-01-26 上海美悦生物科技发展有限公司 一种irak抑制剂及其制备方法和用途
WO2021204589A1 (en) 2020-04-07 2021-10-14 Bayer Aktiengesellschaft Substituted thiazolopyridines, salts thereof and their use as herbicidally active substances
KR20230048358A (ko) * 2020-08-03 2023-04-11 쿠리스 인코퍼레이션 질환 및 장애를 치료하기 위한 조성물 및 방법
WO2022108996A1 (en) * 2020-11-18 2022-05-27 Curis, Inc. Methods of treating diseases and disorders
EP4269409A4 (en) * 2020-12-25 2024-12-11 Medshine Discovery Inc. AMIDE-OXAZOLE COMPOUND
US12178821B2 (en) * 2021-04-08 2024-12-31 Curis, Inc. Combination therapies for the treatment of cancer
CN113402499B (zh) 2021-06-21 2022-05-13 上海勋和医药科技有限公司 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途
TW202328150A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之噻唑并吡啶、其鹽及其作為除草活性物質之用途
TW202328151A (zh) 2021-09-07 2023-07-16 德商拜耳廠股份有限公司 經取代之2,3-二氫[1,3]噻唑并[4,5-b]吡啶、其鹽及其作為除草活性物質之用途
TWI890016B (zh) 2021-12-23 2025-07-11 大陸商杭州多域生物技術有限公司 一種五員并六員化合物、製備方法、藥物組成物和應用
IL316793A (en) * 2022-05-11 2025-01-01 Curis Inc Treating diseases and disorders with compounds that modify IRAK4
CN121969366A (zh) * 2023-10-27 2026-05-01 柯里斯公司 治疗与白介素1β表达降低相关的癌症的方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
ES2102367T3 (es) 1990-05-18 1997-08-01 Hoechst Ag Amidas de acidos isoxazol-4-carboxilicos y amidas de acidos hidroxialquiliden-cianoaceticos, medicamentos que contienen estos compuestos y su utilizacion.
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
ATE391492T1 (de) 1997-07-29 2008-04-15 Alcon Lab Inc Ophthalmische zusammensetzungen enthaltend galaktomannanpolymere und borat
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
DE10023486C1 (de) 2000-05-09 2002-03-14 Schering Ag Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
ES2350837T3 (es) 2003-05-01 2011-01-27 Bristol-Myers Squibb Company Compuestos de pirazol-amida sustituidos con arilo útiles como inhibidores de quinasas.
ATE556067T1 (de) 2003-05-20 2012-05-15 Ajinomoto Kk Modulatoren des vanilloid rezeptors
EP1628661A2 (en) 2003-06-05 2006-03-01 Vertex Pharmaceuticals Incorporated Modulators of vr1 receptor
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
WO2005032493A2 (en) 2003-10-07 2005-04-14 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
MXPA06012104A (es) 2004-04-22 2007-01-25 Bayer Cropscience Lp Metodo y composicion para controlar malas hierbas.
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1655297A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
TW200628159A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp IL-12 modulatory compounds
CN101072775A (zh) 2004-12-17 2007-11-14 伊莱利利公司 新的mch受体拮抗剂
US7902356B2 (en) 2004-12-17 2011-03-08 Eli Lilly And Company Thiazolopyridinone derivates as MCH receptor antagonists
EP1674467A1 (en) 2004-12-22 2006-06-28 4Sc Ag 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors
WO2007058626A1 (en) 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
AU2007215247B2 (en) 2006-02-10 2012-12-13 Transtech Pharma, Llc Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors
GB0606429D0 (en) 2006-03-30 2006-05-10 Novartis Ag Organic compounds
WO2007117465A2 (en) 2006-03-31 2007-10-18 Abbott Laboratories Indazole compounds
WO2007121154A2 (en) 2006-04-11 2007-10-25 Janssen Pharmaceutica, N.V. Substituted benzothiazole kinase inhibitors
RU2459821C2 (ru) 2006-09-07 2012-08-27 Байоджен Айдек Ма Инк. Модуляторы киназы, ассоциированной с рецептором интерлейкина-1
AU2007292924A1 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. IRAK modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
WO2008061109A2 (en) 2006-11-15 2008-05-22 Forest Laboratories Holdings Limited Indazole derivatives useful as melanin concentrating receptor ligands
WO2008073825A1 (en) 2006-12-08 2008-06-19 Exelixis, Inc. Lxr and fxr modulators
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
CA2690619A1 (en) 2007-07-16 2009-01-22 Abbott Laboratories Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases
US20090069288A1 (en) 2007-07-16 2009-03-12 Breinlinger Eric C Novel therapeutic compounds
BRPI0814975A2 (pt) 2007-08-08 2015-02-03 Merck Serono Sa Derivados de 6-amino-pirimidina-4-carboxamida e compostos relacionados que se ligam ao receptor de 1-fosfato de esfingosina (s1p) para o tratamento de esclerose múltipla
NZ587039A (en) 2008-02-13 2013-01-25 Gilead Connecticut Inc 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof
CA2743609A1 (en) 2008-11-19 2010-05-27 Schering Corporation Inhibitors of diacylglycerol acyltransferase
EP2379564A1 (en) 2008-12-19 2011-10-26 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
EP2393781B1 (en) 2008-12-23 2014-03-12 F. Hoffmann-La Roche AG Dihydropyridone ureas as p2x7 modulators
JP5819305B2 (ja) 2009-10-13 2015-11-24 リガンド・ファーマシューティカルズ・インコーポレイテッド 造血成長因子模倣小分子化合物およびそれらの使用
JP2013525370A (ja) 2010-04-22 2013-06-20 ヤンセン ファーマシューティカ エヌ．ベー． ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物
EP2563358A4 (en) 2010-04-30 2013-09-25 Merck Sharp & Dohme INHIBITORS OF PHOSPHOINOSITIDE-DEPENDENT KINASE 1 (PDK1)
HRP20171176T1 (hr) 2010-06-24 2017-10-06 Chemocentryx, Inc. C5ar antagonisti
CN102985426B (zh) 2010-07-13 2015-10-07 弗·哈夫曼-拉罗切有限公司 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
HUE037860T2 (hu) 2010-11-19 2018-09-28 Ligand Pharm Inc Heterociklusos aminok és alkalmazásuk
WO2012084704A1 (en) 2010-12-20 2012-06-28 Merck Serono S.A. Indazolyl triazole derivatives as irak inhibitors
WO2012142125A2 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Plasmodial surface anion channel inhibitors for the treatment or prevention of malaria
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
RU2014120166A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
GB201119401D0 (en) 2011-11-10 2011-12-21 Ucb Pharma Sa Therapeutic agents
KR101385603B1 (ko) 2012-05-17 2014-04-21 한국원자력의학원 벤조티아졸 유도체 및 암 치료를 위한 그의 용도
WO2014003483A1 (en) 2012-06-29 2014-01-03 Hanmi Pharm. Co., Ltd. Fused pyrimidine derivatives having inhibitory activity on fms kinases
HK1210696A1 (en) 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
JP6372666B2 (ja) 2012-11-03 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング サイトメガロウイルスの阻害剤
US9168257B2 (en) 2013-05-22 2015-10-27 Children's Hospital Medical Center Combination therapy for MDS
TWI652014B (zh) 2013-09-13 2019-03-01 美商艾佛艾姆希公司 雜環取代之雙環唑殺蟲劑
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
BR112016015983A2 (pt) * 2014-01-10 2017-08-08 Aurigene Discovery Tech Ltd Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
SMT202400142T1 (it) * 2014-01-13 2024-05-14 Aurigene Oncology Ltd Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro
JP6532474B2 (ja) 2014-02-06 2019-06-19 アッヴィ・インコーポレイテッド ６−ヘテロアリールオキシ−および６−アリールオキシ−キノリン−２−カルボキシアミドならびにその使用
KR20170016500A (ko) 2014-06-20 2017-02-13 오리진 디스커버리 테크놀로지스 리미티드 Irak4 저해제로서의 치환된 인다졸 화합물
AU2016293441A1 (en) 2015-07-15 2018-02-01 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as IRAK-4 inhibitors
CN108024971A (zh) 2015-07-15 2018-05-11 奥列基因发现技术有限公司 作为irak-4抑制剂的取代的氮杂化合物
ES2811136T3 (es) * 2015-08-04 2021-03-10 Rigel Pharmaceuticals Inc Compuestos de benzazol y métodos para obtener y usar los compuestos
US20210292843A1 (en) 2016-10-28 2021-09-23 Children's Hospital Medical Center Treatment of diseases associated with activated irak
MX2020003666A (es) * 2017-10-31 2020-08-03 Curis Inc Compuestos y composiciones para el tratamiento de trastornos hematologicos.

Also Published As

Publication number Publication date
JP7241747B2 (ja) 2023-03-17
MY203827A (en) 2024-07-19
PT3704108T (pt) 2024-06-11
HRP20240700T1 (hr) 2024-08-16
LT3704108T (lt) 2024-06-25
AU2023222890A1 (en) 2023-09-14
IL274248A (en) 2020-06-30
BR112020008214A2 (pt) 2020-10-27
IL315025A (en) 2024-10-01
JP2023071915A (ja) 2023-05-23
PH12020550457A1 (en) 2021-03-22
IL274248B1 (en) 2024-02-01
CN117064897A (zh) 2023-11-17
KR20240130818A (ko) 2024-08-29
US20200345704A1 (en) 2020-11-05
CA3079628A1 (en) 2019-05-09
MX2023010882A (es) 2023-09-27
SG11202002386WA (en) 2020-04-29
EP3704108B1 (en) 2024-04-24
EP4410377A2 (en) 2024-08-07
ES2979273T3 (es) 2024-09-25
KR20200080254A (ko) 2020-07-06
EP3704108A4 (en) 2021-08-25
HUE067356T2 (hu) 2024-10-28
EA202090497A1 (ru) 2020-11-23
EP4410377A3 (en) 2024-11-13
IL308364B1 (en) 2024-10-01
AU2018359248B2 (en) 2023-06-01
IL308364A (en) 2024-01-01
JP2021501145A (ja) 2021-01-14
SMT202400216T1 (it) 2024-07-09
US20190134010A1 (en) 2019-05-09
RS65572B1 (sr) 2024-06-28
NZ762393A (en) 2025-07-25
WO2019089580A1 (en) 2019-05-09
AU2023222890B2 (en) 2025-04-17
KR102697663B1 (ko) 2024-08-21
JP7476380B2 (ja) 2024-04-30
CN111225911A (zh) 2020-06-02
AU2025205341A1 (en) 2025-07-31
EP3704108A1 (en) 2020-09-09
IL274248B2 (en) 2024-06-01
IL308364B2 (en) 2025-02-01
JP2024096919A (ja) 2024-07-17
US10758518B2 (en) 2020-09-01
US20220370422A1 (en) 2022-11-24
CN111225911B (zh) 2023-09-01
DK3704108T3 (da) 2024-06-10
FI3704108T3 (fi) 2024-05-23
SI3704108T1 (sl) 2024-07-31
PL3704108T3 (pl) 2024-07-22
AU2018359248A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2023010882A (es) Compuestos y composiciones para el tratamiento de trastornos hematológicos.
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2020011745A (es) Terapias genicas para los trastornos lisosomales.
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
CL2019002734A1 (es) Isoquinolinas como inhibidores de hpk1.
MX2021009673A (es) Moduladores de ror-gamma.
MX389825B (es) Compuestos y composiciones para tratar trastornos hematologicos.
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
CL2018001899A1 (es) Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock)
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
EA201691134A1 (ru) Новые ингибиторы глутаминазы
JOP20180113B1 (ar) مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية
CL2017000712A1 (es) Pirimidinonas como inhibidores del factor xia
MX379155B (es) Compuestos que inhiben la proteína mcl-1.
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
MX2017006832A (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
EA201691916A1 (ru) Биарильные ингибиторы киназы
ECSP16067303A (es) Heteroarilos y usos de estos
MX386547B (es) Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer.
MX2019010422A (es) Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacionados con la fosfoinositida 3-cinasa delta.
MX2017013886A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
EA201692268A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.